Ginkgo Bioworks (DNA) Stock
Platform for engineering microbes across pharmaceutical and industrial use. Here's the price, business snapshot, and what's worth knowing about Ginkgo Bioworks in October 2026.
Ginkgo Bioworks (ticker: DNA) is a synthetic-biology company that designs and engineers microorganisms for customers across industries, from pharmaceuticals to agriculture and industrial chemicals. The business operates a cell‑programming platform and offers foundry services, partnerships and licensing to generate revenue. With a market capitalisation around $737.9m, Ginkgo is a small‑cap company that has invested heavily in R&D, capacity and acquisitions to expand its platform — a strategy that has weighed on near‑term profitability. Potential upside comes from scalable services, recurring revenues from partnerships and novel product opportunities, but the stock can be volatile: progress depends on scientific success, customer adoption, regulatory outcomes and capital markets. Investors should note the company’s development stage, potential for further fundraising and biotech sector risks. This information is educational only and not personal investment advice; consider your risk tolerance and seek professional advice before investing.
Ginkgo Bioworks (DNA) Stock Forecast
Analyst price target, next 12 months
$28.00
+126.7% vs today's $12.35
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Ginkgo Bioworks have a consensus 12-month target of $28.00, above the current price of $12.35.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend selling Ginkgo Bioworks stock, with a target price of $28 indicating limited growth.
Financial Health
Ginkgo Bioworks is showing strong revenue, cash flow, and profitability metrics, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform potential
Ginkgo’s cell‑programming platform could unlock recurring services and licensing revenue as customers scale, though commercial outcomes and timing can vary.
Partnership momentum
Collaborations and agreements can accelerate revenue and validation, but returns depend on execution and may take time to materialise.
Science and regulation
Scientific progress and regulatory approvals shape long‑term value; investors should expect developmental and policy uncertainties.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
